Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 1.70 is in line with its estimated 1-year average of 1.84, near the low end of its estimated 1-year range (1.70–1.98).
As of 2026-10-06T19:12:43.483Z.
Calculation as of: 2026-10-06T19:12:43.483Z.
Quote observation: 2026-10-06T19:10:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 347a41eedf46a91d1f1a35dde2c997a021a555167078676fef94c90a8032fb0d
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
1.70
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.29
median of 579 covered companies
CURRENT VS SECTOR MEDIAN
-60.37%
vs the sector median at left
Market Cap
$5.22B
PS Ratio
390.16
TTM Avg
715.74
3Y Avg
272.12
5Y Avg
564.99
Market Cap
$5.14B
PS Ratio
N/A
TTM Avg
12.01
3Y Avg
39.75
5Y Avg
43.00
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. Common Stock (MMED) | $5.47B | 1.70 | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.52B | 2.43 | 2.51 | 2.38 | 1.82 |
| CG Oncology Inc. (CGON)vs › | $5.62B | 902.28 | 1844.16 | 3811.91 | 3811.91 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.33B | 5.28 | 4.89 | 3.61 | 4.09 |
| Doximity, Inc. (DOCS)vs › | $5.26B | 8.02 | 10.47 | 14.75 | 18.94 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.22B | 390.16 | 715.74 | 272.12 | 564.99 |
| Sotera Health Company (SHC)vs › | $5.20B | 4.28 | 4.13 | 3.77 | 4.31 |
| Travere Therapeutics, Inc. (TVTX)vs › | $5.17B | 8.75 | 8.06 | 6.05 | 6.39 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.14B | N/A | 12.01 | 39.75 | 43.00 |
| Cogent Biosciences, Inc. (COGT)vs › | $5.14B | N/A | 339.12 | 118.01 | 104.25 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2025Period ended 2025-10-31 | $752,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-31 |
| Q3 FY2025Period ended 2026-01-31 | $790,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-01-31 |
| Q4 FY2025Period ended 2026-04-24 | $837,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-29 |
| Q1 FY2026Period ended 2026-07-31 | $843,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-08 |
| TTM revenue | $3,222,000,000 |
Current P/S: $5,472,222,543 market capitalization ÷ $3,222,000,000 TTM revenue = 1.70x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T19:10:19.000Z. Latest revenue period ended 2026-07-31.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
At 1.70, P/S is below its estimated 1-year median — higher than 5% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
1.70
median
1.84
estimated 1-year high
1.98
P/S Ratio
1.70
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 1.76 |
| 2026-10-02 | 1.72 |
| 2026-10-01 | 1.71 |
| 2026-09-30 | 1.70 |
| 2026-09-29 | 1.75 |
| 2026-09-28 | 1.79 |
| 2026-09-25 | 1.74 |
| 2026-09-24 | 1.78 |
| 2026-09-23 | 1.79 |
| 2026-09-22 | 1.85 |
| 2026-09-21 | 1.84 |
| 2026-09-18 | 1.90 |
| 2026-09-17 | 1.92 |
| 2026-09-16 | 1.95 |
| 2026-09-15 | 1.92 |
| 2026-09-14 | 1.92 |
| 2026-09-11 | 1.96 |
| 2026-09-10 | 1.96 |
| 2026-09-09 | 1.98 |
